|
|
|
24.06.25 - 14:36
|
Cambrooke Celebrates 25 Years of Innovation and a Bold Mission (PR Newswire)
|
|
|
AYER, Mass., June 24, 2025 /PRNewswire/ -- Ajinomoto Cambrooke, Inc., a global leader in medical nutrition, proudly celebrates its 25th anniversary with an expanded mission and refreshed brand identity. The mission—living without limits—is embodied by a new logo featuring a warm "hug"......
|
|
|
|
|
|
|
|
|
06.05.25 - 14:09
|
Forge Biologics Announces Eight Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting (Business Wire)
|
|
|
Oral and poster presentations will highlight data demonstrating the enhanced productivity, recovery, and consistent quality of Forge's FUEL™ AAV manufacturing platform, addressing the industry's need for more efficient manufacturing
COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics (“Forge”), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced that it will deliver eight presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, taking place May 13-17, 2025 in New Orleans, Louisiana. The presentations include two technical session presentations, an oral presentation, and five scientific posters focused on Forge's FUEL™ platform and manufacturing innovations for gene therapies.
“We're proud to share Forge's latest manufacturing advancements, underscoring our commitment to innovation as we help clients deliver transformative gene therapies to patients,” said John Maslowski, CEO and Preside...
|
|
|
05.05.25 - 14:24
|
PCI completes acquisition of sterile fill-finish CDMO Ajinomoto Althea (PBR)
|
|
|
Last month, PCI signed a deal to acquire Ajinomoto Althea, a subsidiary of Japan-based Ajinomoto. This acquisition is part of PCI's investment strategy to enhance its manufacturing capabilities
The post PCI completes acquisition of sterile fill-finish CDMO Ajinomoto Althea appeared first on Pharmaceutical Business review....
|
|
|
02.05.25 - 01:39
|
Als Teil einer Investitionsstrategie in Höhe von 1 Milliarde US-Dollar schließt PCI Pharma Services die Übernahme von Ajinomoto Althea ab und stärkt damit die US-amerikanische Arzneimittelproduktion... (Business Wire)
|
|
|
Neben dem Ausbau der eigenen Infrastruktur von PCI fördert die Übernahme das jüngste Wachstum des CDMO in den Bereichen sterile Abfüllung, fortschrittliche Arzneimittelverabreichungssysteme wie Fertigspritzen und Kartuschen sowie Biologika – einschließlich hochwirksamer Wirkstoffe für Antikörper-Wirkstoff-Konjugate.
PHILADELPHIA--(BUSINESS WIRE)--
Als Teil einer Investitionsstrategie in Höhe von 1 Milliarde US-Dollar schließt PCI Pharma Services die Übernahme von Ajinomoto Althea ab und stärkt damit die US-amerikanische Arzneimittelproduktion für die aseptische Abfüllung von Fertigspritzen und Kartuschen
PCI Pharma Services („PCI“) – ein weltweit führendes Auftragsentwicklungs- und Fertigungsunternehmen (CDMO) mit Schwerpunkt auf innovativen Biopharma-Therapien – hat die Übernahme von Ajinomoto Althea, Inc. („Althea“) abgeschlossen, einem in den USA ansässigen CDMO für sterile Abfüllung und Fertigstellung und Tochtergesellschaft der japanischen Ajinomoto Co., Inc. Für PC...
|
|
|
01.05.25 - 16:03
|
Part of $1 Billion Investment Strategy, PCI Pharma Services Completes Acquisition of Ajinomoto Althea, Enhancing US Drug Product Manufacturing for Aseptic Filling of Prefilled Syringes & Cartridges (Business Wire)
|
|
|
Along with PCI's own robust infrastructure expansions, acquisition furthers CDMO's recent growth in sterile fill-finish, advanced drug delivery systems like prefilled syringes and cartridges, and biologics – including high potent assets for antibody-drug conjugates.
PHILADELPHIA--(BUSINESS WIRE)--PCI Pharma Services (“PCI”) – a leading global contract development and manufacturing organization (CDMO) focused on innovative biopharma therapies – has completed its acquisition of Ajinomoto Althea, Inc. (“Althea”), a US-based sterile fill-finish CDMO and subsidiary of Japan-based Ajinomoto Co., Inc. For PCI, the acquisition is a cornerstone of a multi-year investment strategy spanning facilities in the United States and Europe. In the United States, Althea's assets combine with PCI's existing sterile fill-finish and advanced drug delivery operations to form a world-class, large-scale manufacturing hub in San Diego, complete with state-of-the-art large-scale aseptic facilities for prefilled sy...
|
|
|
25.04.25 - 00:48
|
PCI Pharma Services übernimmt US-amerikanisches CDMO-Unternehmen Ajinomoto Althea, das auf aseptische Abfüllung spezialisiert ist (Business Wire)
|
|
|
Durch die Übernahme entsteht in der Region San Diego ein weltweit führender Großproduktionsstandort mit hochmodernen aseptischen Anlagen für Fertigspritzen, Kartuschen und hochwirksame Formulierungen wie ADCs, der die bestehenden globalen Aktivitäten im Bereich der sterilen Abfüllung und fortschrittlichen Arzneimittelverabreichung ergänzt.
PHILADELPHIA--(BUSINESS WIRE)--PCI Pharma Services („PCI“) – ein weltweit führendes Auftragsentwicklungs- und Fertigungsunternehmen (CDMO) mit Schwerpunkt auf innovativen Biopharma-Therapien – übernimmt alle Anteile an Ajinomoto Althea, Inc. („Althea“), einem in den USA ansässigen CDMO für sterile Abfüll- und Fertigstellungsprozesse und 100-prozentigen Tochterunternehmen der japanischen Ajinomoto Co., Inc. Die Übernahme soll im Mai 2025 abgeschlossen sein und verschafft PCI seinen ersten Produktionsstandort in Nordamerika für Fertigspritzen und Kartuschen – einschließlich Isolatorentechnologie für diese Formate – sowie für die Herstellun...
|
|
|
24.04.25 - 09:03
|
PCI Pharma Services to Acquire US-based Aseptic Fill-Finish CDMO Ajinomoto Althea (Business Wire)
|
|
|
Acquisition creates a world-class large-scale manufacturing hub in San Diego region with state-of-the-art aseptic facilities for prefilled syringes, cartridges and high potent formulations such as ADCs, complementing existing global sterile fill-finish and advanced drug delivery operations.
PHILADELPHIA--(BUSINESS WIRE)--PCI Pharma Services (“PCI”) – a leading global contract development and manufacturing organization (CDMO) focused on innovative biopharma therapies – is acquiring an entire equity stake in Ajinomoto Althea, Inc. (“Althea”), a US-based sterile fill-finish CDMO and 100% subsidiary of Japan-based Ajinomoto Co., Inc. Scheduled for completion in May 2025, the acquisition provides PCI with its first-ever North American manufacturing location for prefilled syringes and cartridges – including isolator technology for these formats – as well as high potent manufacturing suitable for antibody-drug conjugates (ADCs).
Althea's robust clinical- and commercial-stage services for injecta...
|
|
|
07.04.25 - 23:48
|
XFRA: CAPITAL ADJUSTMENT INFORMATION - 09.04.2025 - US0097071007 (XETRA)
|
|
|
Das Instrument AJI0 US0097071007 AJINOMOTO CO. ADR 1 EQUITY wird cum Kapitalmassnahme gehandelt am 08.04.2025 und ex Kapitalmassnahme am 09.04.2025
The instrument AJI0 US0097071007 AJINOMOTO CO. ADR 1 EQUITY is traded cum capital adjustment on 08.04.2025 and ex capital adjustment on 09.04.2025...
|
|
|
|
|
|
|
25.03.25 - 01:36
|
Shared Meals Lead to Greater Happiness: Survey (Nippon)
|
|
|
By Adriana Reinecke Washington, March 24 (Jiji Press)--New research has found a robust, positive relationship between sharing meals and subjective well-being. According to the recently published 2025 World Happiness Report, the less frequently one eats alone, the greater their sense of happiness. The survey by U.S. analytics company Gallup Inc. and Japanese food maker Ajinomoto Co. wa......
|
|
|
20.03.25 - 13:03
|
Ajinomoto Bio-Pharma Services Awarded CDMO Leadership Awards (PR Newswire)
|
|
|
Ajinomoto Bio-Pharma Services recognized in "Global Biologics" category Forge Biologics, a member of Ajinomoto-Bio-Pharma Services, recognized in "Global Cell & Gene Therapy" category SAN DIEGO, March 20, 2025 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading......
|
|
|
13.02.25 - 17:03
|
Prolific Machines Announces the Appointment of Former Forge Biologics Executive, Christina Perry, as CFO Setting the Stage for Optogenetics Leader′s Biopharmaceutical Commercial Ramp Up (Business Wire)
|
|
|
Christina Perry, MSA, CPA, former Chief Financial Officer (CFO) of Forge Biologics, recently acquired by Ajinomoto Co., has been appointed as CFO of Prolific Machines to support the company's meteoric growth as it works towards building a resilient, sustainable business.
CFO leadership appointment signals Prolific's continued momentum and preparation to onboard pharmaceutical and biotechnology customers onto its Photomolecular platform as it continues to make rapid technology and capability advances.
EMERYVILLE, Calif.--(BUSINESS WIRE)--Prolific Machines, a biotechnology company using light to control biology, announces the appointment of Christina Perry to its expert team. Christina Perry joins Prolific as CFO where she will be charged with scaling Prolific's growth and financial systems as it continues to focus on expanding its commercial reach. Perry will also leverage her deep pharmaceutical and CDMO expertise to help Prolific achieve its ambitious business goals.
Prolific Machines is advancing the...
|
|
|
|
|
|
|
|
|
20.06.24 - 23:49
|
XFRA : NEW INSTRUMENT AVAILABLE - 21.06.2024 - US0097071007 (XETRA)
|
|
|
Das Instrument AJI0 US0097071007 AJINOMOTO CO. ADR 1 EQUITY hat seinen ersten Handelstag am 21.06.2024: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP N
The instrument AJI0 US0097071007 AJINOMOTO CO. ADR 1 EQUITY has its first trading date on 21.06.2024: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP N...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
